MacroGenics (MGNX) vs Sol-Gel Technologies (SLGL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
MacroGenics (MGNX) has outperformed Sol-Gel Technologies (SLGL) over the past year, gaining 106.4% versus a gain of 75.5%. Over five years, SLGL leads with a -22.8% price change compared with -82.0% for MGNX. Sol-Gel Technologies is the larger company by market cap ($230.3 million vs $226.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MGNX | SLGL |
|---|---|---|
| Share price | $3.55 | $70.34 |
| Market cap | $226.14M | $230.29M |
| 1-day change | 0.00% | -2.23% |
| YTD return | +120.50% | +70.73% |
| 1-year return | +106.40% | +75.52% |
| 5-year return | -82.02% | -22.85% |
| EPS (TTM) | $-1.70 | $-5.61 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.08 | $97.97 |
| 52-week low | $1.29 | $28.81 |
| Distance from 52-week high | -30.12% | -28.20% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +125.35% | +116.80% |
| Average volume | 621.73K | 55.30K |
| Shares outstanding | 63.70M | 3.27M |
| Employees | 293 | 28 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MGNX has outperformed SLGL by 30.9 percentage points over the past year.
About MacroGenics
MGNX stock →MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials.
Health Care · Biotechnology: Pharmaceutical Preparations · 293 employees
About Sol-Gel Technologies
SLGL stock →Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea.
Health Care · Biotechnology: Pharmaceutical Preparations · 28 employees
MGNX vs SLGL FAQ
Which is bigger, MacroGenics or Sol-Gel Technologies?
Sol-Gel Technologies (SLGL) is larger, with a market capitalization of $230.29M compared with $226.14M for MacroGenics (MGNX).
Which stock has performed better over the past year, MGNX or SLGL?
MGNX returned +106.40% over the past 12 months, compared with +75.52% for SLGL (price return, excluding dividends). Past performance does not predict future results.
Are MacroGenics and Sol-Gel Technologies in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.